176 related articles for article (PubMed ID: 19414985)
1. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.
Mohammadizadeh F; Naimi A; Rajabi P; Ghasemibasir H; Eftekhari A
Indian J Med Sci; 2009 Apr; 63(4):152-62. PubMed ID: 19414985
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
Marotti JD; Collins LC; Hu R; Tamimi RM
Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
4. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
5. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study.
Al Tamimi DM; Shawarby MA; Ahmed A; Hassan AK; AlOdaini AA
BMC Cancer; 2010 May; 10():223. PubMed ID: 20492711
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
Verma S; Bal A; Joshi K; Arora S; Singh G
APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
[TBL] [Abstract][Full Text] [Related]
7. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma.
Mohammadizadeh F; Ghasemibasir H; Rajabi P; Naimi A; Eftekhari A; Mesbah A
Cancer Biomark; 2009; 5(1):1-8. PubMed ID: 19242056
[TBL] [Abstract][Full Text] [Related]
8. Biologic profiling of lymph node negative breast cancers by means of microRNA expression.
Janssen EA; Slewa A; Gudlaugsson E; Jonsdottir K; Skaland I; Søiland H; Baak JP
Mod Pathol; 2010 Dec; 23(12):1567-76. PubMed ID: 20818337
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.
Livasy CA; Karaca G; Nanda R; Tretiakova MS; Olopade OI; Moore DT; Perou CM
Mod Pathol; 2006 Feb; 19(2):264-71. PubMed ID: 16341146
[TBL] [Abstract][Full Text] [Related]
10. MYC amplification in subtypes of breast cancers in African American women.
Naab TJ; Gautam A; Ricks-Santi L; Esnakula AK; Kanaan YM; DeWitty RL; Asgedom G; Makambi KH; Abawi M; Blancato JK
BMC Cancer; 2018 Mar; 18(1):274. PubMed ID: 29523126
[TBL] [Abstract][Full Text] [Related]
11. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
12. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
[TBL] [Abstract][Full Text] [Related]
14. Expression of luminal and basal cytokeratins in human breast carcinoma.
Abd El-Rehim DM; Pinder SE; Paish CE; Bell J; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
J Pathol; 2004 Jun; 203(2):661-71. PubMed ID: 15141381
[TBL] [Abstract][Full Text] [Related]
15. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.
Ihemelandu CU; Leffall LD; Dewitty RL; Naab TJ; Mezghebe HM; Makambi KH; Adams-Campbell L; Frederick WA
J Surg Res; 2007 Nov; 143(1):109-18. PubMed ID: 17950079
[TBL] [Abstract][Full Text] [Related]
16. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
17. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
18. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Expression of Amine Oxidase Proteins in Breast Cancer.
Sun WY; Choi J; Cha YJ; Koo JS
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261141
[TBL] [Abstract][Full Text] [Related]
20. Frequency of breast cancer subtypes among African American women in the AMBER consortium.
Allott EH; Geradts J; Cohen SM; Khoury T; Zirpoli GR; Bshara W; Davis W; Omilian A; Nair P; Ondracek RP; Cheng TD; Miller CR; Hwang H; Thorne LB; O'Connor S; Bethea TN; Bell ME; Hu Z; Li Y; Kirk EL; Sun X; Ruiz-Narvaez EA; Perou CM; Palmer JR; Olshan AF; Ambrosone CB; Troester MA
Breast Cancer Res; 2018 Feb; 20(1):12. PubMed ID: 29409530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
